EUVIMEDEUVIMED entdecken
Crossref

Transcriptomic Investigation of Small Cell Lung Cancer Survival Outcomes

Lambert, Kyle, Victor W. Henderson, Julien Sage

Stanford Digital Repository · 06.06.2024

DOI: 10.25740/zz382fj3653 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stanford Digital Repository, erschienen am 06.06.2024. Verfasst von Lambert und 3 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small cell lung cancer (SCLC) is a highly aggressive and metastatic cancer with a poor prognosis. Studying SCLC in clinical settings is challenging due to its rapid progression. To bridge a gap between clinical outcomes and findings from preclinical studies that allow mechanistic understandings of the disease, this study investigates the role of the Tuberous Sclerosis Complex 1 (TSC1) gene, a tumor suppressor, in SCLC patient survival. RNA sequencing data from patients with SCLC was used to assess TSC1 expression levels. A total of 66 patients with limited-stage SCLC (Stage I to III) were stratified into high and low TSC1 expression groups as determined by an mRNA FPKM expression above or below the cohort median of 4.79, respectively. Alongside demographic and clinical characteristics, overall survival and progression-free survival were analyzed as our main outcomes using Kaplan-Meier curves and Cox regression models. The median overall survival for patients with low TSC1 expression was 14 months (95% CI: 11 - 33), compared to 25 months (95% CI: 19 - 48) for patients with high TSC1 expression. The hazard ratio for overall survival in the low TSC1 expression group compared to the high TSC1 expression group was 2.18 (95% CI: 1.07 - 4.46), indicating more than a twofold increased risk of death in the low TSC1 group. Interestingly, patients with high TSC1 expression who received chemotherapy or radiation therapy had the best overall survival outcomes. Our findings suggest that low TSC1 expression may be a potential prognostic marker for poor overall survival in SCLC patients. TSC1 expression in a patient’s tumor may also influence the effectiveness of chemotherapy and radiation therapy. Further studies are needed to explore the underlying mechanisms and strengthen the epidemiology of related outcomes.

Schlagwörter

small cell lung cancerTSC1tuberous sclerosis complex 1tumor suppressor gene expressionprognostic factorsoverall survivalprogression-free survivallimited-stage small cell lung cancerchemotherapy responseradiotherapy response

Zitieren

APA

Lambert, Kyle, Henderson, V. W., & Sage, J. (2024). Transcriptomic Investigation of Small Cell Lung Cancer Survival Outcomes. Stanford Digital Repository. https://doi.org/10.25740/zz382fj3653

Vancouver

Lambert, Kyle, Henderson VW, Sage J. Transcriptomic Investigation of Small Cell Lung Cancer Survival Outcomes. Stanford Digital Repository. 2024. doi:10.25740/zz382fj3653

BibTeX
@article{Lambert2024,
  author = {Lambert and Kyle and Henderson, Victor W. and Sage, Julien},
  title = {Transcriptomic Investigation of Small Cell Lung Cancer Survival Outcomes},
  journal = {Stanford Digital Repository},
  year = {2024},
  doi = {10.25740/zz382fj3653}
}
Kostenlos starten →